KembaraXtra-Medicine – Atelectasis


Atelectasis refers to the collapse of part or all of the lung, resulting in loss of lung volume. It is broadly classified into two major types. Obstructive atelectasis, the most common form, occurs when an airway is blocked, such as by a mucus plug, foreign body, or tumor, leading to resorption of air in the alveoli beyond the obstruction. Nonobstructive atelectasis occurs without airway blockage and may result from external compression (for example, pleural effusion), surfactant abnormalities, lung scarring, or reduced ventilation of part of the lung.


Atelectasis is frequently seen in postoperative patients, individuals with lung or chest wall injury, and those receiving mechanical ventilation. Dependent regions of the lung are particularly prone to collapse. Prior asbestos exposure is associated with a characteristic form known as rounded atelectasis. There is no clear racial or sex predilection.


Clinical presentation varies widely. Some patients are asymptomatic, while others develop cough, dyspnea, and hypoxemia. On physical examination, findings over the affected area may include decreased or absent breath sounds, dullness to percussion, reduced tactile fremitus, and diminished vocal resonance.


The causes of atelectasis are diverse and include airway obstruction (such as tumors, mucus plugs, or foreign bodies), extrinsic bronchial compression from masses or enlarged cardiac structures, pleural disease (including pleural effusion, pneumothorax, mesothelioma, or rounded atelectasis), and alveolar injury from aspiration, toxic inhalation, infection, or acute respiratory distress syndrome. Additional contributors include chest wall abnormalities, impaired respiratory mechanics due to pain or neuromuscular disease, and repetitive shear injury during positive-pressure ventilation.


The differential diagnosis includes bronchogenic carcinoma, pneumonia, pulmonary infarction, and pleural effusion. Diagnostic evaluation typically begins with a chest x-ray, which often suggests volume loss. Thoracic ultrasonography can help distinguish atelectasis from pleural effusion or consolidation. Chest CT scanning is useful when endobronchial obstruction or external compression is suspected, and prone positioning may help differentiate dependent atelectasis from true consolidation. Bronchoscopy is reserved for selected cases to evaluate or relieve airway obstruction.


Management focuses on re-expanding the lung and addressing the underlying cause. Nonpharmacologic measures include deep breathing exercises, early mobilization and ambulation, incentive spirometry, and airway clearance techniques such as positive expiratory pressure devices, cough-assist devices, and chest physiotherapy. In selected patients, tracheal suctioning or bronchoscopy may be required to remove mucus plugs or foreign bodies.


Acute management may include supplemental oxygen, positive-pressure ventilation (such as CPAP or PEEP), mucolytic therapy for mucus plugging, bronchodilators when indicated, and adequate pain control, especially in postoperative or trauma patients to allow effective ventilation. Large pleural effusions, hemothorax, or empyema should be drained when contributing to lung collapse.


Chronic management depends on the cause and may involve ongoing airway clearance therapies, treatment of underlying lung disease, debulking or stenting of obstructing endobronchial lesions, or removal of sources of external compression such as effusions or masses. Prognosis varies and is largely determined by the underlying etiology and the patient’s overall clinical condition.


Patients benefit from education emphasizing frequent position changes, sitting upright when possible, early mobilization, and adherence to breathing exercises. Referral to pulmonology or interventional pulmonology is appropriate when bronchoscopy, tumor management, or specialized airway interventions are required.

KembaraXtra-Medicine – Ataxia Telangiectasia (AT)


Ataxia telangiectasia (AT) is a rare autosomal recessive childhood disorder caused by defective DNA repair. It is a multisystem condition characterized by progressive cerebellar ataxia, abnormal movements (e.g., choreoathetosis), oculocutaneous telangiectasias, recurrent infections from immune dysfunction, marked sensitivity to ionizing radiation, and an increased risk of malignancy. The ICD-10CM code is G11.3 (cerebellar ataxia with defective DNA repair).


AT occurs in about 1 in 40,000 live births, affects males and females equally, and typically begins in early childhood (often ages 1–5 years). It is considered the second most common autosomal recessive ataxia after Friedreich ataxia. The causative gene is ATM (mapped to chromosome 11q22–23), and many different mutations have been identified. The ATM protein is a kinase activated by double-stranded DNA breaks, triggering pathways for cell cycle arrest, DNA repair, or apoptosis. ATM is also important for V(D)J recombination in developing lymphocytes, which helps explain the immune problems seen in AT.


Children often develop normally until they begin walking, when gait and truncal ataxia become noticeable. Over time, symptoms can include slurred speech, progressive difficulty coordinating eye movements (including oculomotor apraxia), polyneuropathy, choreoathetosis, delayed physical and sexual development, and features of premature aging (such as early graying and skin/subcutaneous fat changes). Motor skills gradually decline, and by the second decade, many individuals require a wheelchair for at least part of the day. As the condition progresses, oromotor and swallowing difficulties can increase the risk of aspiration. Cognitive function is often initially normal and may decline early, then tends to plateau around about 10 years of age, though motor impairment can make school performance and timed testing look worse than true cognitive ability.


Telangiectasias are highly suggestive of AT but often appear later—typically after age 6—which can delay diagnosis. They commonly involve the bulbar conjunctiva (sometimes mistaken for conjunctivitis) and can also appear on the ears, cheeks, corners of the eyes, neck, nasal bridge, and flexor forearm creases. Skin findings may include café-au-lait macules, hypopigmented macules, or melanocytic nevi. Immune dysfunction affects 60%–80% of patients and stems from B-cell and T-helper problems. IgA is absent in many patients, IgE is low/absent in most, and IgM may be elevated; this predisposes to recurrent sinopulmonary infections. While the immune deficiency itself is typically not progressive, repeated infections and aspiration can contribute to bronchiectasis later in life.


Neuropathology includes progressive cerebellar injury with loss of Purkinje cells, and later changes may involve posterior columns and spinocerebellar tracts, with reports of anterior horn cell involvement and peripheral nerve changes. Cancer risk becomes increasingly important with age: beyond about 10 years, the incidence has been described as roughly 1% per year, with an overall lifetime risk around 30%–40%, most commonly leukemia and lymphoma. Carriers (heterozygotes) usually do not have classic AT symptoms but may have a higher malignancy risk at younger ages.


Diagnosis is based on the clinical picture (early-onset progressive ataxia plus telangiectasia and/or immune abnormalities), family history, and supportive testing. The differential for early-onset ataxia includes Friedreich ataxia, abetalipoproteinemia, acquired vitamin E deficiency, AOA1/AOA2, AT-like disorder, various spinocerebellar ataxias, certain metabolic diseases (e.g., Hartnup disease, maple syrup urine disease), and leukodystrophies. Helpful laboratory findings can include abnormal immunoglobulin levels, and serum α-fetoprotein, which is elevated in more than 95% of children with AT older than about 8 months. Some patients have acanthocytes on smear. Immunoblot testing for ATM protein is highly sensitive/specific, and many affected individuals have little to no detectable ATM protein. Brain MRI or CT typically shows cerebellar atrophy during childhood; imaging may also show findings compatible with telangiectasia-related changes.


There is no proven disease-specific cure, so management focuses on monitoring and reducing complications. This includes close surveillance for infections and cancers, consideration of IV immunoglobulin for those with frequent/severe infections, and sometimes prophylactic antibiotics. Routine preventive care is important, including influenza and pneumococcal vaccination. Because of radiation sensitivity, exposure to ionizing radiation should be minimized, including limiting diagnostic radiographs when possible. Swallowing should be monitored as needed to reduce aspiration risk, and physical/occupational therapy supports mobility and helps prevent contractures. Some studies suggest possible symptomatic improvement with glucocorticoids, thought to influence ATM splicing and preserve some kinase activity, but this is not established as definitive therapy. Antioxidants such as vitamin E are sometimes used empirically, though strong evidence is limited.


Prognosis is serious due to multisystem involvement, but survival has improved; many individuals now live beyond 25 years, and some into their 40s or 50s. Morbidity and mortality are most often related to recurrent infections or malignancy. Ongoing care typically involves coordinated referral to immunology, neurology, gastroenterology/nutrition, rehabilitation services, and genetic counseling.

KembaraXtra-Medicine – Ataxia


Ataxia most commonly refers to an unsteady, uncoordinated gait, but the term is also used more broadly to describe incoordination that can involve the limbs, trunk, speech and swallowing muscles, and even eye movements. Many people first notice imbalance while walking, frequent falls, or “bumping into” walls. On exam, gait ataxia often appears as a broad-based, unsteady gait with difficulty performing tandem walking (heel-to-toe).


Ataxia can affect all ages and both sexes equally. Hereditary ataxias are estimated to affect about 1 in 50,000 people in the United States, and overall prevalence has been reported around 13.9 per 10,000. Hereditary forms often peak in young adulthood, while new ataxia after age 65 is commonly related to stroke. Risk factors include a family history of ataxia, heavy alcohol use, hypothyroidism, chronic anticonvulsant use (especially phenytoin), celiac disease, and cerebrovascular disease. The most common inherited ataxia in the U.S. is Friedreich ataxia (autosomal recessive), followed by autosomal dominant spinocerebellar ataxias, with SCA3 being a common subtype.


Symptoms typically progress from mild unsteadiness to frequent falls. People may also report double vision or a sensation that the environment is moving, and speech can become slurred and harder to understand. Physical findings may include nystagmus and other abnormal eye movements, slurred speech, dysmetria (past-pointing) on finger-to-nose or heel-to-shin testing, and dysdiadochokinesia (difficulty with rapid alternating movements). Gait is often wide-based with trouble turning and a tendency to veer or sway, and tandem gait is usually abnormal.


Causes of ataxia are diverse and are often grouped into cerebellar ataxia (from cerebellar dysfunction or its connections) and sensory ataxia (from impaired proprioception due to dorsal column disease, dorsal root ganglionopathy, or large-fiber neuropathy). Etiologies include genetic disorders (e.g., Friedreich ataxia, spinocerebellar ataxias, ataxia-telangiectasia, episodic ataxias), vascular events (cerebellar stroke), infections and inflammatory conditions (postinfectious cerebellitis, multiple sclerosis, HIV, Whipple disease), tumors, structural abnormalities (Arnold–Chiari malformation), toxins (alcohol, certain chemotherapies, heavy metals, solvents), medications (especially phenytoin), endocrine disease (hypothyroidism), and nutritional deficiencies (vitamin E, B1, B12). Autoimmune and paraneoplastic syndromes are also important considerations, including gluten ataxia, Hashimoto encephalopathy, anti-GAD65 ataxia, and subacute cerebellar degeneration associated with antibodies such as anti-Yo.


Evaluation should be systematic and prioritize reversible causes. A careful family history can guide genetic testing, and acute-onset ataxia should prompt urgent assessment for stroke with appropriate brain imaging. Brain MRI (with and without contrast when appropriate) is strongly recommended to assess for infarct, hemorrhage, tumor, inflammation, or cerebellar atrophy; CT is used when MRI is not feasible. Lumbar puncture may be needed if infection, inflammatory disease, or leptomeningeal malignancy is suspected. When cancer is suspected or known, a paraneoplastic antibody panel may be appropriate, recognizing that neurologic paraneoplastic syndromes can precede detectable malignancy.


Common baseline laboratory testing often includes a complete blood count, comprehensive metabolic panel and liver tests, thyroid function tests, and screening for infections such as HIV and syphilis (RPR). Nutritional and metabolic evaluation may include folate, vitamin B12 (with methylmalonic acid/homocysteine when B12 is “low-normal”), vitamin E (interpreted with cholesterol), and tests for celiac disease (e.g., tissue transglutaminase antibodies). Copper and ceruloplasmin may be checked when Wilson disease is a concern. Electromyography and nerve conduction studies are useful when sensory ataxia due to large-fiber neuropathy or myeloneuropathy is suspected. Selected cases may require genetic testing, autoimmune markers (e.g., anti-GAD65, anti-thyroid antibodies), or specialized metabolic testing depending on age of onset and clinical pattern.


Treatment depends on the underlying cause whenever possible. Reversible contributors are addressed directly—for example, vitamin replacement for deficiencies, treating hypothyroidism, stopping or adjusting offending toxins/medications, and disease-specific therapy for immune or inflammatory causes when indicated. Sudden ataxia must be evaluated and treated as possible stroke using standard acute stroke pathways. For many genetic or degenerative ataxias, care is largely supportive and focused on preventing complications and maintaining function, including monitoring for associated problems such as neuropathy or cardiac disease in certain inherited forms.


Rehabilitation is central for nearly all patients with ataxia. Physical therapy can improve gait and balance, occupational therapy can support daily function and safety, and speech therapy can help with dysarthria and swallowing issues. Long-term outlook varies: reversible causes can improve significantly with treatment, while many inherited ataxias are progressive. Neurology referral is recommended for diagnostic guidance, genetic evaluation when appropriate, and ongoing management. Families should be educated on fall prevention and home safety measures to reduce injury risk, and a gluten-free diet is recommended when ataxia is related to celiac disease.